AI-assisted, human-published
08/11/2026 /Funding Events
Vedanta Biosciences Secures $60 Million Funding for Gastrointestinal Disease Therapies
Vedanta Biosciences secures significant funding to support microbiome-based oral therapies for gastrointestinal diseases and the Phase 3 RESTORATiVE303 study of VE303 for preventing recurrent C. difficile infection.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com